Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Carcinoma, Non-Small-Cell Lung 2Sezary Syndrome 1Sarcoma, Kaposi 1Recurrence 1Lymphoma 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

zanolimumab 3mogamulizumab 3denileukin diftitox 2Vorinostat 2Vitamin B 12 2Panobinostat 2Folic Acid 210-propargyl-10-deazaaminopterin 2resminostat 1ontuxizumab 1navitoclax 1N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 1MAC-ST-001 1Interleukin-12 Subunit p35 1Fentanyl 1Fenretinide 1Duration of Therapy 1Bexarotene 1A-dmDT390-bisFv(UCHT1) protein 1(N(1),N(12))bis(ethyl)-6,7-dehydrospermine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sezary Syndrome × Bexarotene × Clear all
NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡